Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial
European Journal of Cancer · 2023-03 · 182 · 57-65
DOI: 10.1016/j.ejca.2022.12.027 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023-03. Verfasst von Xuan Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking Universi…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: At present, immune monotherapy and combination therapy has not shown satisfactory effects on acral melanoma, and still no standard treatment is available for advanced acral melanoma. Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354). METHODS: Patients with pathologically confirmed, locally unresectable or metastatic treatment native acral melanoma received 250 mg apatinib once daily and camrelizumab 200 mg once every two weeks intravenously every 28-day cycle. The primary end-point was objective response rate and the secondary end-points were disease control rate, overall survival, progression-free survival and safety. RESULTS: Thirty patients were recruited between January 2015 and January 2022. Among them, 21 (70.0%) had stage IV, and a median tumour burden was 50 mm (range: 11-187). Objective response rate was 24.1%, and 7 of 29 patients had an anti-tumour response, including partial response (n = 5) and complete response (n = 2). Disease control rate was 82.8%, median progression-free survival was 7.39 months (confidence interval: 3.65-9.92), and median overall survival was 13.4 months (confidence interval: 1.9-25.0). Grade 3-4 treatment-related toxicity (grade 3 50.5%; grade 4 3.3%) included transaminase elevations, proteinuria, leukocytopenia, vomiting, diarrhea and drug-induced liver injury. No treatment-related mortality occurred. The mutations of TTN, MUC16, VPS13D, ALPK2 and SCUBE1 showed significant alterations with survival outcome. CONCLUSIONS: Apatinib combined with camrelizumab showed manageable safety profile and reasonable anti-tumour activity in advanced acral melanoma patients as first-line therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Bei…
Zitieren
APA
Wang, X., Wu, X., Yang, Y., Xu, W., Tian, H., Lian, B., Chi, Z., Si, L., Sheng, X., Kong, Y., Zhou, L., Mao, L., Li, S., Tang, B., Yan, X., Bai, X., Guo, J., & Cui, C. (2023). Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. European Journal of Cancer, 182, 57-65. https://doi.org/10.1016/j.ejca.2022.12.027
Vancouver
Wang X, Wu X, Yang Y, Xu W, Tian H, Lian B, et al. Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial. European Journal of Cancer. 2023;182:57-65. doi:10.1016/j.ejca.2022.12.027
BibTeX
@article{Wang2023,
author = {Wang, Xuan and Wu, Xiaowen and Yang, Yue and Xu, Weiran and Tian, Hui and Lian, Bin and Chi, Zhihong and Si, Lu and Sheng, Xinan and Kong, Yan and Zhou, Li and Mao, Lili and Li, Siming and Tang, Bixia and Yan, Xieqiao and Bai, Xue and Guo, Jun and Cui, ChuanLiang},
title = {Apatinib combined with camrelizumab in advanced acral melanoma patients: An open-label, single-arm phase 2 trial},
journal = {European Journal of Cancer},
year = {2023},
volume = {182},
pages = {57--65},
doi = {10.1016/j.ejca.2022.12.027}
}
EUVIMED